» Articles » PMID: 10485468

Frequent Somatic Mutations of the Beta-catenin Gene in Intestinal-type Gastric Cancer

Overview
Journal Cancer Res
Specialty Oncology
Date 1999 Sep 15
PMID 10485468
Citations 64
Authors
Affiliations
Soon will be listed here.
Abstract

The increased level of cytoplasmic beta-catenin through the mutations to either beta-catenin or adenomatous polyposis coli (APC) has been proposed as an important oncogenic step in various tumors. Gastric cancer showed frequent genetic alterations of the APC gene, and the risk for gastric cancer in familial adenomatosus polyposis patients is 10 times higher than that in the general population. These findings raise the possibility that mutations of beta-catenin may also be associated with the development of gastric cancer. We detected seven somatic mutations in a portion of exon 3 encoding for the glycogen synthase kinase 3beta phosphorylation consensus region of the beta-catenin gene in 43 gastric cancers. All of these mutations were missense mutations, of which five are in the highly conserved aspartic acid 32 and two are in serine 29; all of these seven mutations were detected exclusively in intestinal-type gastric cancers (7 of 26; 26.9%), but not in the diffuse-type (0 of 17). We concluded that disruption of the APC/beta-catenin/T cell factor-lymphoid enhancer binding factor pathway might play an important role especially in the development of intestinal-type gastric cancer.

Citing Articles

Overexpression of SHANK2 contributes malignant outcomes as a Hippo pathway regulator in gastric cancer.

Arakawa H, Komatsu S, Kiuchi J, Imamura T, Nishibeppu K, Kamiya H Am J Cancer Res. 2025; 15(1):363-374.

PMID: 39949934 PMC: 11815361. DOI: 10.62347/NZMO2658.


Overexpression of Tetraspanin31 contributes to malignant potential and poor outcomes in gastric cancer.

Takashima Y, Komatsu S, Ohashi T, Kiuchi J, Kamiya H, Shimizu H Cancer Sci. 2022; 113(6):1984-1998.

PMID: 35307915 PMC: 9207375. DOI: 10.1111/cas.15342.


The immune microenvironment in gastric adenocarcinoma.

Zavros Y, Merchant J Nat Rev Gastroenterol Hepatol. 2022; 19(7):451-467.

PMID: 35288702 PMC: 9809534. DOI: 10.1038/s41575-022-00591-0.


TRIM37 contributes to malignant outcomes and CDDP resistance in gastric cancer.

Nishibeppu K, Komatsu S, Kiuchi J, Kishimoto T, Takashima Y, Shoda K J Cancer. 2021; 12(2):316-325.

PMID: 33391428 PMC: 7739001. DOI: 10.7150/jca.47577.


Expression patterns of seven key genes, including β-catenin, Notch1, GATA6, CDX2, miR-34a, miR-181a and miR-93 in gastric cancer.

Jafari N, Abediankenari S, Hosseini-Khah Z, Valizadeh S, Torabizadeh Z, Zaboli E Sci Rep. 2020; 10(1):12342.

PMID: 32704077 PMC: 7378835. DOI: 10.1038/s41598-020-69308-0.